2020
DOI: 10.1080/19420862.2020.1815995
|View full text |Cite
|
Sign up to set email alerts
|

An accelerated surface-mediated stress assay of antibody instability for developability studies

Abstract: High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and poor conformational stability, but protein aggregation remains a challenging property to predict. Among different types of stresses, air–water and solid–liquid interfaces are well known to potentially trigger protein instability and induce aggregation. Yet, in contrast to the increasing number… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
20
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 34 publications
(20 citation statements)
references
References 85 publications
0
20
0
Order By: Relevance
“…The surface-mediated stress assay and hydrophobic nanoparticle surface-mediated stress assay could be used to screen for any aggregation risk in therapeutic proteins. 34,35 Agitation, dropping and friability tests are typically recommended to assess aggregate formation risks in therapeutic proteins that use vials, syringes, or IV bags during formulation development [36][37][38][39] ; however, these tests are challenging to perform in the early stages of development as they require large sample amounts. 3D-HLD automatically measured the particle concentrations of aggregates in 30 formulations of two therapeutic proteins (Fig.…”
Section: Discussionmentioning
confidence: 99%
“…The surface-mediated stress assay and hydrophobic nanoparticle surface-mediated stress assay could be used to screen for any aggregation risk in therapeutic proteins. 34,35 Agitation, dropping and friability tests are typically recommended to assess aggregate formation risks in therapeutic proteins that use vials, syringes, or IV bags during formulation development [36][37][38][39] ; however, these tests are challenging to perform in the early stages of development as they require large sample amounts. 3D-HLD automatically measured the particle concentrations of aggregates in 30 formulations of two therapeutic proteins (Fig.…”
Section: Discussionmentioning
confidence: 99%
“…They have been expressed in mammalian cell lines and been purified as a minimum with both a Protein A purification and a size-exclusion chromatography step yielding a purity above 95 % as measured with SE-HPLC (data not shown). mAb 2 has previously been characterized in detail, and is denoted as WT in references 25,26 and as mAb-C in reference. 27 Theoretical pI is 6.9, 8.1, 8.4 and 8.4 for mAb 1-4 respectively.…”
Section: Methodsmentioning
confidence: 99%
“…Design, characterisation and expression of the HzATNP antibodies have been performed as described in detail previously 30,37 . After expression, all antibody samples were stored in aliquots at roughly 5-10 mg/mL in either 20mM HEPES buffer pH = 7.4, 150mM NaCl, with 0.01 % (v/v ) Tween (HS buffer) or 2mM HEPES buffer pH = 7.4, 15mM NaCl, with 0.01 % (v/v ) Tween (LS buffer) at -80 • C. Protein stocks were thawed on ice and shock frozen using liquid nitrogen, up to a maximum of three freeze-thaw cycles.…”
Section: Hzatnp Antibody Variantsmentioning
confidence: 99%
“…This library represents an ideal model system for conceptual investigation as it has been characterized in detail to show distinct changes in the protein biophysical properties between the individual variants. 37 We assess the impact of the changes between variants on the non-specific binding to single-stranded DNA, a common non-specificity ligand which is a valuable indicator for the overall propensity of non-specific interactions also in vivo 27,33,38 . By establishing microfluidic diffusional sizing (MDS) 39,40 (Figure 1d) as a tool for probing antibody non-specificity, we identify that non-specific binding of HzATNP antibodies to DNA at physiological salt conditions is driven by a patch of amino-acid residues that engage in hydrogen bonding.…”
Section: Introductionmentioning
confidence: 99%